BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial

Affiliation auteurs!!!! Error affiliation !!!!
TitreBCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial
Type de publicationJournal Article
Year of Publication2017
AuteursPetrella T., Copie-Bergman C., Briere J., Delarue R., Jardin F., Ruminy P., Thieblemont C., Figeac M., Canioni D., Feugier P., Fabiani B., Leroy K., Parrens M., Andre M., Haioun C., Salles G.A, Gaulard P., Tilly H., Jais J.P, Molina T.J
JournalANNALS OF ONCOLOGY
Volume28
Pagination1042-1049
Date PublishedMAY
Type of ArticleArticle
ISSN0923-7534
Mots-clésBCL2, cell of origin, diffuse large B-cell lymphoma, Immunohistochemistry, MYC, prognosis
Résumé

{Background: Our aim was to evaluate whether the cell of origin (COO) as defined by the Hans algorithm and MYC/BCL2 coexpression, which are the twomain biological risk factors in elderly patients treated with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisolone (R-CHOP), maintain their prognostic value in a large prospective clinical trial. Patients and methods: We evaluated 285 paraffin-embedded samples from patients (60-80 years of age) enrolled in the Lymphoma Study Association trial LNH03-6B who were treated with R-CHOP. We correlated the COO defined by the transcriptome according to the Wright algorithm with that defined by the Hans algorithm in a subset of 62 tumors with available frozen tissue samples. Results: The non-germinal center B-cell-like phenotype according to the Hans algorithm and BCL2 expression (but not MYC and BCL2 coexpression) predicted worse progression-free survival [hazard ratio (HR) = 1.78
DOI10.1093/annonc/mdx022